Omeros Corp (OMER) Stock Price, Quote & News

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology

Sector: Healthcare

Phone: 206 676 5000

Website: www.omeros.com

Address:

The Omeros Building, 201 Elliott Avenue West, Seattle, United States

kreftslag Aug. 19 at 11:54 AM

$OMER moderna up 100% on cancer vaccine

1 · Reply

EddieH2020 Aug. 19 at 7:11 AM

$KURA $OMER That’s so cute lol: https://stocktwits.com/EddieH2020/message/662017097

2 · Reply

rongside Aug. 19 at 3:45 AM

$OMER Some diseases have a distinct etiology that can be treated with a specific intervention or drug. Others are more complex and in effect form part of a complex biologic system which cascades through the body affecting its smooth function (multiple organ isruption syndrome). In such cases there are multiple potential interventions along the cascade pathway which address a part of the problem. Omeros' complement treatments interject themselves high up in the cascade process thus preventing (mitigating) the broad detrimental downstream cascade that in so many cases is lethal. All this while leaving the core immune system INTACT. The broad market does not recognise this yet. They will become progressively impressed with sequential sales increases, which I feel are inevitable. For them to truly understand the significance of Yartemlea (and Zaltenibart) they need to see it utilised in additional indications. Hyperinflammatory ARDS is such an indication.

1 · Reply

resq1 Aug. 19 at 3:21 AM

$OMER wow joe owns more shares than me, I need to step up my game

1 · Reply

hoffspeed Aug. 19 at 1:53 AM

$OMER I see what you are upto Joseph Schocken....Rock and roll...nice 500K share holding.

2 · Reply

Arad288 Aug. 18 at 9:56 PM

$OMER this thing is been trading $.16 up and down for few days now with some volume ( maybe less today ) I am not surprised that people take profit a bit here . Just watch your taxes . Don’t forget the 3.8% over $250 k and your state tax ( if applies ) plus capital gain( short or long) Not a tax advice , just a reminder

2 · Reply

robertward Aug. 18 at 9:31 PM

$OMER Fridays option expiration is holding down our precious…

2 · Reply

hoffspeed Aug. 18 at 8:31 PM

$OMER Golden cross happening soon...Few more days

0 · Reply

hoffspeed Aug. 18 at 8:14 PM

$OMER I have a "hunch" that the first milestone payment ($25 to $50) million, due anyday will be the catalyst that pumps it.

3 · Reply

hoffspeed Aug. 18 at 8:12 PM

$OMER Healthy consolidation going on. Bull flagging until the next move up in the short term. The coiling is getting tight, should make the next move upwards end of the week. $20+ soon.

0 · Reply

Omeros reports Q2 adjusted EPS 2c vs (24c) last year

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Omeros Earnings Call Transcript: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Omeros Earnings release: Q2 2026

Aug 12, 2026, 4:30 PM EDT - 6 days ago

Omeros Quarterly report: Q2 2026

Aug 12, 2026, 4:02 PM EDT - 6 days ago

Omeros Corporation Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 8:00 AM EDT - 9 days ago

Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026

2026-08-03T12:41:41.000Z - 15 days ago

Omeros grants new technology add-on payment status to Yartemlea

Aug 3, 2026, 8:30 AM EDT - 16 days ago

CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®

2026-07-27T14:15:25.000Z - 22 days ago

AstraZeneca miss ‘clear positive’ for Omeros, says H.C. Wainwright

AZN

2026-07-27T14:15:17.000Z - 22 days ago

Omeros up 11% to $10.89 after AstraZeneca study failure

AZN

Jul 13, 2026, 2:16 PM EDT - 5 weeks ago

Omeros Corporation Investigated by the Portnoy Law Firm

Jun 26, 2026, 2:11 PM EDT - 7 weeks ago

Omeros stock crashes on regulatory setback: buy the dip?

2026-06-26T15:30:11.000Z - 7 weeks ago

Omeros price target lowered to $33 from $40 at H.C. Wainwright

2026-06-26T12:35:20.000Z - 7 weeks ago

Omeros announces CHMP adopts negative opinion on MAA for narsoplimab

Jun 26, 2026, 8:30 AM EDT - 7 weeks ago

Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA

Jun 18, 2026, 1:00 PM EDT - 2 months ago

Omeros Transcript: AGM 2026

Jun 15, 2026, 8:30 AM EDT - 2 months ago

Omeros Announces Webcast Details for Annual Meeting of Shareholders

2026-06-12T13:45:42.000Z - 2 months ago

Omeros trading resumes

2026-06-12T13:35:42.000Z - 2 months ago

Omeros trading halted, volatility trading pause

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 3 months ago

Omeros Quarterly report: Q1 2026

2026-05-13T20:27:08.000Z - 3 months ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)

May 13, 2026, 4:02 PM EDT - 3 months ago

Omeros Corporation Reports First Quarter 2026 Financial Results

May 11, 2026, 4:02 PM EDT - 3 months ago

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

2026-05-04T12:45:05.000Z - 3 months ago

Kyverna Therapeutics appoints Nadia Dac as chief commercial officer

KYTX

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Omeros Proxy statement: Proxy filing

2026-04-16T14:14:18.000Z - 4 months ago

Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA

Apr 16, 2026, 8:45 AM EDT - 4 months ago

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 5 months ago

Omeros Annual report: Q4 2025

2026-03-31T20:05:48.000Z - 5 months ago

Omeros reports Q4 EPS $1.22, consensus 36c

Mar 31, 2026, 4:02 PM EDT - 5 months ago

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Mar 26, 2026, 8:45 AM EDT - 5 months ago

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Mar 21, 2026, 3:23 AM EDT - 5 months ago

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

2026-02-17T14:15:38.000Z - 6 months ago

Omeros announces completion of nonhuman primates OncotoX-AML study

Feb 17, 2026, 8:45 AM EST - 6 months ago

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Jan 27, 2026, 9:00 AM EST - 7 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 7, 2026, 6:50 PM EST - 7 months ago

Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 4:30 PM EST - 7 months ago

Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 7 months ago

Omeros Press release: FDA Announcement

Dec 26, 2025, 6:36 PM EST - 8 months ago

Omeros Announces New Date for YARTEMLEA® Approval Conference Call

Dec 24, 2025, 9:05 AM EST - 8 months ago

US FDA approves Omeros' drug to treat dangerous transplant complication

Dec 24, 2025, 9:00 AM EST - 8 months ago

FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

Dec 1, 2025, 8:30 AM EST - 9 months ago

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros' Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Nov 13, 2025, 4:30 PM EST - 9 months ago

Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 9 months ago

Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:11 PM EST - 9 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 11, 2025, 8:30 AM EST - 10 months ago

Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025

Oct 16, 2025, 8:30 AM EDT - 10 months ago

Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group

Oct 15, 2025, 11:54 AM EDT - 10 months ago

Can OMER stock retain Novo Nordisk driven gains over the long-term?

Oct 15, 2025, 9:17 AM EDT - 10 months ago

Novo Nordisk to Pay Omeros Up to $2.1 Billion For Blood Disease Drug

NVO

Oct 15, 2025, 8:32 AM EDT - 11 months ago

Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push

NVO

Oct 15, 2025, 8:30 AM EDT - 11 months ago

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Sep 2, 2025, 8:45 AM EDT - 1 year ago

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Jun 27, 2025, 8:30 AM EDT - 1 year ago

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025

May 15, 2025, 4:05 PM EDT - 1 year ago

Omeros Corporation Reports First Quarter 2025 Financial Results

May 12, 2025, 5:05 PM EDT - 1 year ago

Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025

May 12, 2025, 10:35 AM EDT - 1 year ago

Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026

May 6, 2025, 9:16 AM EDT - 1 year ago

FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date

Apr 10, 2025, 9:10 AM EDT - 1 year ago

Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program

Apr 8, 2025, 9:00 AM EDT - 1 year ago

Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:02 PM EDT - 1 year ago

Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results

Mar 26, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025

Mar 21, 2025, 9:15 AM EDT - 1 year ago

Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program

Feb 20, 2025, 9:10 AM EST - 1 year ago

Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA

Feb 14, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings

Feb 10, 2025, 9:00 AM EST - 1 year ago

Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program

Jan 16, 2025, 9:15 AM EST - 1 year ago

Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint

Dec 19, 2024, 9:15 AM EST - 1 year ago

Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA

Dec 10, 2024, 8:45 AM EST - 1 year ago

Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting

kreftslag Aug. 19 at 11:54 AM

$OMER moderna up 100% on cancer vaccine

1 · Reply

EddieH2020 Aug. 19 at 7:11 AM

$KURA $OMER That’s so cute lol: https://stocktwits.com/EddieH2020/message/662017097

2 · Reply

rongside Aug. 19 at 3:45 AM

1 · Reply

resq1 Aug. 19 at 3:21 AM

$OMER wow joe owns more shares than me, I need to step up my game

1 · Reply

hoffspeed Aug. 19 at 1:53 AM

$OMER I see what you are upto Joseph Schocken....Rock and roll...nice 500K share holding.

2 · Reply

Arad288 Aug. 18 at 9:56 PM

2 · Reply

robertward Aug. 18 at 9:31 PM

$OMER Fridays option expiration is holding down our precious…

2 · Reply

hoffspeed Aug. 18 at 8:31 PM

$OMER Golden cross happening soon...Few more days

0 · Reply

hoffspeed Aug. 18 at 8:14 PM

$OMER I have a "hunch" that the first milestone payment ($25 to $50) million, due anyday will be the catalyst that pumps it.

3 · Reply

hoffspeed Aug. 18 at 8:12 PM

$OMER Healthy consolidation going on. Bull flagging until the next move up in the short term. The coiling is getting tight, should make the next move upwards end of the week. $20+ soon.

0 · Reply

Niuniucat Aug. 18 at 8:11 PM

$OMER why it trade within such a tight price range ? 😉

0 · Reply

Jbaffs Aug. 18 at 6:41 PM

$OMER the biggest catalyst is using #yartemela as a prophilactic, given to aptients before surgery as a prevenattive. I think that quadruples the Mkt size, that and two more indications< ARDS and one other going into the hopper. The Era of parabolic growth has begun!!!

0 · Reply

Jbaffs Aug. 18 at 6:35 PM

$OMER Such smart accumilation. They know the stock is up 500% in 14 months so their making it look like it will pull back and not make a new 52 week high, hoping to get the stock out of weak hands. Once there is none left the stock will go up on much higher volume. If they announced the $100 M Novo milestone payment, I think the stock would gap to $22

2 · Reply

Fmyl54 Aug. 18 at 5:36 PM

$OMER have we had any short covering yet?

1 · Reply

TRYII Aug. 18 at 5:25 PM

$OMER Interesting tight $0.25 range for second day in a row. I think this is healthy and new buyers coming in here to create a new, stronger floor.

1 · Reply

StatsGuru Aug. 18 at 4:54 PM

$OMER Greg, common get one more exciting news for our investors!! We need to keep the ball rolling.....

1 · Reply

Niuniucat Aug. 18 at 4:45 PM

$OMER $19

0 · Reply

Slifka Aug. 18 at 4:30 PM

$OMER $30 today folks.

2 · Reply

SadyK189 Aug. 18 at 3:16 PM

Mid-Day Update: 2/2 🚀 🎯 Levels respected perfectly: $XOS → called at 3.92 → went till 5.37 (+37%)🔥 $CDTG → called at 3.07 → went till 3.70 (+21%)✅ $OMER → called at 11.20 → went till 17.28 (+54%)📈 All levels shared earlier (in detailed posts) and reacting cleanly.

1 · Reply

resq1 Aug. 18 at 3:16 PM

$OMER We shoulda closed 17.38 yesterday,.. couple cents off https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=https://www.youtube.com/watch%3Fv%3DQCdXSzMAL4s&ved=2ahUKEwjf7-atu6qWAxU0nu4BHXdVG1kQwqsBegQIXxAB&usg=AOvVaw1PGMATuDoIrGPfmUEMifpQ

0 · Reply

capntrps Aug. 18 at 2:43 PM

$OMER would like to see some strength on a down day in the market. Additionally, would like to break out to a new range higher. Maybe a little soon for any additional moves up w/o other positive catalysts or BO talk. Who knows...

0 · Reply

111ggg Aug. 18 at 2:19 PM

$OMER As I mentioned yesterday, good chance it retracts back to 15 where I will pounce the buy botton. If that doesnt happen, I simply ride out the future with my owned shares.

0 · Reply

Market Cap	1.26B
Revenue (ttm)	0.00
Net Income (ttm)	-3.35M
EPS (ttm)	N/A
PE Ratio	6.30
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-1.89

Volume	1,234,600
Avg Vol	2,168,372
Day's Range	N/A - N/A
Shares Out	72.38M
Stochastic %K	84%
Beta	2.54
Analysts	Sell
Price Target	$44.00